Amarantus Reports 2014 Financial Results and Business Overview
Amarantus BioScience Opens Investigational New Drug (IND) Application With the U.S. Food and Drug Administration Allowing the Start of a Phase 2b Program of Eltoprazine in Parkinson's Disease Levodopa-Induced Dyskinesia
Amarantus to Present at the Neurotech Investing and Partnering Conference on Tuesday, April 7, 2015
Amarantus to Present Positive Alzheimer's Disease Biomarker Data on the LymPro Test(R) at the 12th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders
Amarantus Announces First Alzheimer's Biomarker Services Collaboration for LymPro Test(R) With Anavex Life Sciences Corp.
Amarantus Announces Publication in BRAIN of Eltoprazine Phase 2a Clinical Study for Treating Parkinson's Disease Levodopa-Induced Dyskinesia
Amarantus to Present at the 17th Annual BIO CEO & Investor Conference on February 10, 2015
Amarantus Forms Alzheimer's Disease Diagnostics Scientific Advisory Board